Document Title Antipsychotics Prescribing Guidelines for Schizophrenia

Size: px
Start display at page:

Download "Document Title Antipsychotics Prescribing Guidelines for Schizophrenia"

Transcription

1 Document Title Antipsychotics Prescribing Guidelines for Schizophrenia Document Description Document Type Prescribing Guidance Service Application Medicines Management Version 1.0 Policy Reference no. Lead Author(s) Name Ajibola Gbadebo Job Title Interim Locality Pharmacist - DPH Change History Version Control Version Date Comments 1.0 July 2012 New guidelines issued Link with National Standards National Heath Service Litigation Authority Care Quality Commission National Institute of Clinical Excellence (NICE) Guidance National Patient Safety Agency West Midlands Quality Review Essence of Care Aims Standards IG Toolkit Key Dates Day Month Year Ratification Date Review Date 1

2 Executive Summary Sheet Document Title: Antipsychotics Prescribing Guidelines for Schizophrenia Please tick ( ) as appropriate This is a new document within the Trust This is a revised document within the Trust What is the purpose of this document? To provide guidance on the pharmacological treatment available for schizophrenia with Dudley and Walsall Mental Health Partnership NHS Trust (DWMHPT). Guidance to be audited in line with CQUIN for 2012/13 What key issues does this document explore? Drug choice and Monitoring recommendations for Schizophrenia Who is this document aimed at? All DWMHT clinic service leads, all clinicians including medical, non medical prescribers and Pharmacists Business Administration Managers General Practitioners Dudley PCT Walsall PCT What other policies, guidance and directives should this document be read in conjunction with? Medicines Management Policy Physical Health Monitoring Policy How and when will this document be reviewed? Annually via the Medicines Management Committee 2

3 Document Index Pg 1 Introduction 4 2 Scope 4 3 Recommended Procedure for Antipsychotic Use Antipsychotics use in Schizophrenia Algorithm 6 4 Selecting Antipsychotics for Schizophrenia & Prescribing Formulary Antipsychotic Selection Table Relative Adverse Effects Profile of Antipsychotic Drugs 9 5 Dosages Before prescribing High Dose Antipsychotics Equivalent doses of Antipsychotics 11 6 Monitoring Requirementts 13 7 Antipsychotics in Specials Groups Elderly patients including those with Dementia Pregnancy & Breast Feeding 13 Appendices Pg no 1 Data collection tool for Compliance with Antipsychotics in Schizophrenia Formulary / Guidelines 14 2 Schizophrenia Quick Reference Guide 16 3

4 1 Introduction 1.1 Schizophrenia is usually accompanied by other co-morbid illnesses such as anxiety, substance misuse and depression. Antipsychotics should only be prescribed by a specialist psychiatrist. There is no first line antipsychotic drug which is suitable for all patients. 1.2 This document reflects current NICE guidelines on Schizophrenia. It is strongly advised that the use of these recommendations should be balanced with consideration of the patient s clinical circumstances, their preferences and attitudes. 1.3 Prescribing audits will be undertaken to check standards and levels of uptake of this prescribing guideline 2 Scope 2.1 The guideline covers antipsychotic use in the management and treatment of schizophrenia across the various stages of the illness, including prodromal presentations, first-episode, relapse prevention and treatment-resistant illness. 2.2 It is beyond the scope of this guideline to include a recommended approach to treatment in pregnancy states, breast feeding patients and rapid tranquillization, which is not specific to schizophrenia. 2.3 Target Population: 18-65years of age diagnosed with schizophrenia 3 Recommended Procedure for Antipsychotic Use 3.1 Initiation of antipsychotic treatment for schizophrenia should be by specialist psychiatrist. 3.2 ECG and other necessary investigations should be checked before antipsychotics are prescribed in accordance with NICE guidelines and Trust standards for Physical Health monitorings. 3.3 antipsychotics should be offered first. 3.4 Patient and carers should be duly provided appropriate information to enable jointly made decisions to improve patient experience. A decision about which medicine is prescribed should be made jointly with the individual based on an informed discussion of the relative benefits and side effects of medicines. 3.5 Adequate documentation (Clinical rating scale information, response to treatment, full details of medications used, and the rationale for changing medication) should be completed for each treatment choice. A proforma for clinical report will ensure that all information is adequately captured. 4

5 3.6 All antipsychotic prescribing should be prescribed by their generic names with appropriate formulations stipulated to avoid ambiguities. 3.7 Where a choice exists between brand, generic, or different formulations (e.g slow release) of a recommended antipsychotic, initiate treatment with a form that is likely to be best tolerated to enhance adherence with treatment. 3.8 The antipsychotic should be initiated at a low dose and slowly titrate the dose to the optimum effective dose, or the maximum manufacturers recommended dose or BNF recommendations, evaluating response from two weeks, ensure optimum duration of four to six weeks before switching unless adverse effects occurs. 3.9 Where there is no/insufficient response after maintaining the maximum tolerated dose for at least four weeks the antipsychotic should be withdrawn gradually, whilst introducing an alternative antipsychotic Sedatives may be required for short term behavioural control if needed If any steps of treatment differ from the recommendation, the rationale should be adequately documented Recommendations are illustrated in the following algorithm and table (PTO) 5

6 3.13 Antipsychotics use in Schizophrenia Algorithm Choice of antipsychotic (AP) should be guided by considering the clinical characteristics of the patient and the efficacy and side effect profiles of the medication. Stages may be skipped depending on the clinical picture or history of antipsychotic failures. Returning to an earlier stage may be justified by history of past response Stage 1 First Episode Schizophrenia. Early trial of FGA Partial or or SGA n-response as single antipsychotic. First episode patients usually require lower antipsychotic dosing and should be closely monitored due to greater sensitivity to medication side effects. FGA daily dosages mg chlorpromazine equivalents Duration of therapy: 1 2 years If intolerant or non-adherent, offer Long Acting Injectable antipsychotic Inadequate adherence to oral medication at any stage, may call for a long acting antipsychotic preparation Partial Stage or 2 n-response Trial of a single SGA or FGA different to one tried in stage 1 for up to 4wks Partial or n-response Stage 3 CLOZAPINE Partial or n-response A treatment refractory evaluation should be considered at stage 4-6 Partial or n-response Stage 4 CLOZAPINE + FGA or SGA Stage 5 Trial of a single agent FGA or SGA (not tried in stage 1 or 2) n-response FGA: First Generationantipsychotic SGA: Second Generation Antipsychotic Stage 6 Time limited combination Therapy e.g. SGA + FGA, combination of SGAs (FGA or SGA) & other non antipsychotic agents 6

7 4 Selecting Antipsychotics for Schizophrenia & Prescribing Formulary In Dudley and Walsall Mental HealthTrust preferred choice of antipsychotics are based on current available evidences with following criteria: Consideration of patients medical history or other co-morbidities e.g. substance abuse & medication history. The relative importance of side effect profile of the antipsychotic to the patients Acquisition costs of different available therapies: Consideration should always be given to medication acquisition cost. If all other things are equal (i.e. efficacy, safety, tolerability), then less expensive antipsychotic relevant to the clinical situation should be the first choice Longer term clinical and economic outcomes Formulation of antipsychotics Prescribers are advised to refer to the latest editions of the Maudsley Guidelines, or the Psychotropic Drug Directory (Stephen Bazire) and BNF ( Key RED AMBER GREEN Antipsychotics that can only be initiated by DWMHPT specialist prescribers, learning disabilities specialists, or practitioners with a special interest in mental health only (non-formulary in all other NHS trusts in the Black Country Cluster) Antipsychotics which may be initiated by DWMHPT specialist prescribers and can be recommended to GP or other prescriber involved in the care of the patient in the primary care community, under a shared care protocol and local enhanced services. Continuing care guidance with continuing support may be provided by the DWMHPT, where appropriate. Antipsychotics that may be initiated by medical and non-medical prescribers across the primary and secondary care sections PURPLE BLACK Antipsychotics that can only be initiated after approval by the Medicines Management Committee or through the approved process specified by the Medicines Management Committee. The Managed Entry process can be found on trust website at: <link>. All newly introduced psychotropic drugs and new formulations of existing ones are automatically restricted for use in the Trust until the Dudley and Walsall Medicines Management Committee (MMC) undertake informed evaluation of its use and place in therapy within the Trust Antipsychotics that should not be prescribed in the Trust 7

8 4.1 Antipsychotic Selection Table Classification Formulation Comments First Generation Antipsychotics Phenothiazines Chlorpromazine Chlorpromazine Chlorpromazine Suppositories Available from special order manufacturers or specialist importing companies Fluphenazine (unlicensed) Available from special order manufacturers or specialist importing companies Levomepromazine Levomepromazine Pericyazine Perphenazine Prochlorphenazine (Stemetil) Promazine Trifluoperazine Benperidol Haloperidol Haloperidol Flupentixol Zuclopenthixol Zuclopenthixol Acetate Pimozide Amisulpride Sulpiride First Generation Antipsychotics Butyrophenones First Generation Antipsychotics Thioxanthenes First Generation Antipsychotics Diphenylbutylpiperidines First Generation Antipsychotics Substituted Benzamides Second Generation Antipsychotics Aripiprazole Consider less expensive antipsychotic of Aripiprazole Clozapine Olanzapine Olanzapine emboate Paliperidone Quetiapine Risperidone Asenapine Flupentixol decanoate Fluphenazine decanoate Haloperidol decanoate Olanzapine palmoate Paliperidone palmitate Pipothiazine palmitate Risperdal Consta Zuclopenthixol decanoate *** Different oral formulations. Rapid Acting IM Sublingual Depots and Long-Acting s Depot Depot Depot Long Acting Long Acting Depot Long Acting Long Acting equal efficacy, tolerabity and safety first. 8

9 4.2 Relative Adverse Effects Profile of Antipsychotic Drugs Drug Sedation Weight Gain Diabetes EPSE Ach HTN Prolactin First Generation Antipsychotics (FGAs) Benperidol + + +/ Chlorpromazine (oral) Chlorphromazine (IM) Flupentixol (oral) Flupentixol (depot) Fluphenazine (depot) Haloperidol (oral) Haloperidol (depot) + + +/ Levomepromazine Perphenazine Pimozide Prochlorperazine Promazine Sulpiride Trifluoperazine + Zuclopenthixol (oral) Zuclopenthixol (depot) Second Generation Antipsychotics (SGAs) Amisulpride Aripiprazole - +/ Olanzapine (oral) / Olanzapine (depot) Paliperidone Quetiapine Risperidone (oral) Risperidone (depot) +++: high incidence/severity ++: moderate +:low -:very low. Other side effects include sexual adverse effects, metabolic side effects (The Maudsley Prescribing Guidelines in Psychiatry th Edition) 5 Dosages 5.1 Dosage titration should be within the range identified in the British National Formulary (BNF) or Summary of Product Characteristics (SmPC). 5.2 Initiation should be at the lower end of the licensed dosage range and increased gradually, depending on response or behaviour and the nature and tolerability of side effects, aiming to achieve an adequate trial at the optimum dosage with good adherence. 5.3 Any dose increase of antipsychotic should be performed gradually at a minimum of weekly intervals. This will help to identify a clinical response at the lowest effective dose and may reduce the risk of neuroleptic malignant syndrome. 5.4 There is no evidence that dosages above the recommended range have any advantage in the treatment of acute psychotic episodes. 9

10 5.5 Regular combined antipsychotic medication should not be prescribed routinely, except for short periods when switching from one antipsychotic to another or in a time limited trial where there is a partial response after trial of successive agents. 5.6 Doses above the usual therapeutic range should be time limited (e.g. 4-6 weeks) and response evaluated using standard clinical ratings. If improvement has not occurred with the higher than usual dosage in this time frame, then treatment should be reviewed. 5.7 Before prescribing High Dose Antipsychotics: High dose antipsychotic therapy (HDAT) is defined by the Royal College of Psychiatrists (RCPsych) as a total daily dose of a single antipsychotic which exceeds the upper limit stated in the British National Formulary (BNF), or a total daily dose of two or more antipsychotics which exceeds the BNF maximum as calculated by percentages using the antipsychotic dose ready reckoner (see appendix 2) Example calculation: Zuclopenthixol depot 300mg weekly (50%) and olanzapine 15mg daily (75%) = 50% + 75%= 125% (>100% therefore high dose ) 5.8 Current evidence does not justify the routine use of HDAT. If high doses are to be used in an individual case this should be time limited, with clear reasons and treatment plan documented in the patients notes. 5.9 Use of PRN or when required antipsychotic medication should also be included in calculating the total daily dose. The use of PRN medication should be reviewed regularly Practitioners administering doses of antipsychotics above BNF maximum doses must check the notes for the rationale behind this decision and confirm that the dose is documented in the notes or should assure themselves of the rationale for high dose prescribing The decision to prescribe HDAT should involve an individual riskbenefit assessment by a Consultant Psychiatrist, the patient (where possible) and the multidisciplinary team 5.12 A baseline ECG should be performed to exclude cardiac contraindications such as QT prolongation. If an ECG is not performed, the reason should be documented in the patients notes. The ECG should be repeated after a few days, and then every one to three months in the early stages of high dose treatment and then periodically as clinically indicated. In the event of a prolonged QT interval (QTc > 470ms for men, QTc > 500ms for women) the prescribing should be halted and further advice sought (a cardiology assessment is recommended). 10

11 5.13 Off-license or off-label would apply to the use of HDAT and must be considered and discussed with the patient. Any discussion and decision reached should be documented in the notes including the risks and benefits, the aims and when and how the outcome will be assessed Therapeutic progress should be monitored at least once every three months, preferably with the aid of a rating scale such as the Positive and Negative Symptoms of Schizophrenia Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS). If no significant progress is observed then the use of HDAT should cease and the future treatment plan should be reviewed. Continued use of HDAT where there is no improvement in clinical response must be fully and clearly justified in the case notes. In this instance responsible medical officer should consider seeking a second opinion from another senior colleague The justification for dosages outside the range given in the BNF or SmPC and target outcomes of the HDAT should also be documented in the clinical records Before HDAT is used the diagnosis and previous treatment should be reviewed, including doses and duration. Concordance with treatment should be reviewed and alternative antipsychotics and adjunctive drug therapies have been considered In a small proportion of cases HDAT may be justified provided the safety implications are considered and monitoring requirements are observed. These include; partial response or red blood result with clozapine, when switching from one antipsychotic to another (shortterm cross-tapering) and as a temporary measure with depot medication during an acute exacerbation of illness However, there is insufficient evidence for the use of HDAT for relapse prevention in schizophrenia, persistent aggression and treatment resistant schizophrenia Consideration should also be given to the increased treatment costs associated with HDAT and the possibility of GPs being unwilling to assume prescribing responsibility after the patient is discharged if HDAT is being used Equivalent doses of Antipsychotics: Antipsychotics vary greatly in potency and are expressed as differences in chlorpromazine equivalents. These values should be seen as a rough guide when transferring from one conventional drug to another. The dose-response relationship is usually well defined for SGAs, and it is inappropriate to convert second generation antipsychotic dose into equivalents. 11

12 12

13 6. Monitoring Requirements 6.1 Regular review of the medication regimen should address the following: Therapeutic efficacy, in terms of change in clinical domains such as symptoms, behaviour and cognition Side effects of treatment Medication adherence Physical health 6.2 Refer to Trust Physical Health Monitoring Policy on the Trust website for further information 7 Antipsychotics in Special Groups 7.1 All medications should be used in lower doses with children and elderly patients and with great caution in women who are pregnant or breastfeeding Elderly patients including those with Dementia The use of antipsychotic medications for the treatment of behavioral symptoms in elderly patients with dementia has not been shown to be effective and is associated with an increased risk of mortality Pregnancy & Breast Feeding Up to date advice should be obtained and the lowest effective dose used. Specific enquiries regarding the use of antipsychotics during lactation can be addressed to the National Medicines Information Service via their website: The benefits of breast-feeding to the mother and infant must be weighed against the risks due to exposure in the infant. A treatment that allows breast-feeding should be explored rather than recommending not breast-feed. (Contact pharmacy for medicines information). 13

14 Appendix 1 - Data collection tool for Compliance with Antipsychotics in Schizophrenia Formulary / Guidelines Quarter 4 (March 2013) Initials of Data collector: Today s date: Patient identifier: DOB: Male Female Location/Unit: RMO: Initiation Date(s) Current Antipsychotic(s) Frequency & Doses 1. / 2. / 3. / High cost agents therapy 1. If aripirazole was prescribed, was this used as a first line agent? Depot/ long acting injections 2. If paliperidone was prescribed, was this used as a first line agent? 3. If Risperdal Consta was prescribed, was this used as a first line agent? 4. Was the patient initially offered an oral antipsychotic agent? 4(a) If not, was the reason documented? 14

15 5. Is the antipsychotic(s) prescribed generically 5(a) If not, was the reason documented? 6. Was the dosage(s) of prescribed antipsychotic(s) within the BNF limits? 6(a) If not, was the reason documented? 7. If a patient was prescribed prn (as required) antipsychotic medication, was the clinical indications stated? 8. If a patient was prescribed prn (as required) antipsychotic medication is there evidence that treatment was reviewed in accordance to the Trust guidelines? 9. Is there evidence that the patient received physical health monitoring? 10. Is combination antipsychotic therapy prescribed? 10 (a) If so, was the reason documented? 15

16 Appendix 2 Schizophrenia Quick Reference Guide Classification Formulation Comments First Generation Antipsychotics Phenothiazines Chlorpromazine Chlorpromazine Chlorpromazine Suppositories Available from special order manufacturers or specialist importing companies Fluphenazine (unlicensed) Available from special order manufacturers or specialist importing companies Levomepromazine Levomepromazine Pericyazine Perphenazine Prochlorphenazine (Stemetil) Promazine Trifluoperazine First Generation Antipsychotics Butyrophenones Benperidol Haloperidol Haloperidol First Generation Antipsychotics Thioxanthenes Flupentixol Zuclopenthixol Zuclopenthixol Acetate First Generation Antipsychotics Diphenylbutylpiperidines Pimozide First Generation Antipsychotics Substituted Benzamides Amisulpride Sulpiride Second Generation Antipsychotics Aripiprazole Consider less expensive antipsychotic of equal efficacy, tolerabity and safety first. Aripiprazole Clozapine Olanzapine Olanzapine emboate Rapid Acting IM Paliperidone Quetiapine Risperidone Asenapine Sublingual Depots and Long-Acting s Flupentixol decanoate Depot Fluphenazine decanoate Depot Haloperidol decanoate Depot Olanzapine palmoate Long Acting Paliperidone palmitate Long Acting Pipothiazine palmitate Depot Risperdal Consta Long Acting Zuclopenthixol decanoate Long Acting Key RED AMBER GREEN PURPLE BLACK Antipsychotics that can only be initiated by DWMHPT or prescribers in primary care with an interest in mental health Antipsychotics which may be initiated by DWMHPT and can be recommended to primary care under a shared care agreement or local enhanced service Antipsychotics that may be initiated by prescribers across the primary and secondary care Antipsychotics that can only be initiated after approval by the Medicines Management Committee via Managed Entry Antipsychotics that should not be prescribed in the Trust 16

17 DECISION ALGORITHM Choice of antipsychotic (AP) should be guided by considering the clinical characteristics of the patient and the efficacy and side effect profiles of the medication. Stages may be skipped depending on the clinical picture or history of antipsychotic failures. Returning to an earlier stage may be justified by history of past response Partial or n-response Stage 1 First Episode Schizophrenia. Early trial of FGA or SGA as single antipsychotic. First episode patients usually require lower antipsychotic dosing and should be closely monitored due to greater sensitivity to medication side effects. FGA daily dosages mg chlorpromazine equivalents Duration of therapy: 1 2 years If intolerant or non-adherent, offer Long Acting Injectable antipsychotic Inadequate adherence to oral medication at any stage, may call for a long acting antipsychotic preparation Partial Stage or n- 2 Trial of a single SGA or FGA different to one tried in stage 1 for up to 4wks Partial or n-response Stage 3 CLOZAPINE Partial or n-response Stage 4 CLOZAPINE + FGA or SGA A treatment refractory evaluation should be considered at stage 4-6 Partial or n-response Stage 5 Trial of a single agent FGA or SGA (not tried in stage 1 or 2) n-response Stage 6 Time limited combination Therapy e.g. SGA + FGA, combination of SGAs (FGA or SGA) & other non antipsychotic agents FGA: First Generationantipsychotic SGA: Second Generation Antipsychotic 17

High Dose Antipsychotic Therapy (HDAT) guideline

High Dose Antipsychotic Therapy (HDAT) guideline Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857

More information

Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service

Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact

More information

Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses

Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses HPFT Medicines Formulary lists the APDs that have been approved for use, however, it does not

More information

High Dose Antipsychotic Therapy (HDAT) guideline

High Dose Antipsychotic Therapy (HDAT) guideline Document level: Trustwide (TW) Code: MP18 Issue number: 4 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Authors details Michael Slater (Clinical Pharmacist, tel. 01625

More information

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information

MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION

MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION Page 1 of 16 Table of Contents Why we need this Policy... 3 What the Policy is trying to do... 3 Which stakeholders have been involved

More information

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance] SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm

More information

High Dose Antipsychotic Medication Policy

High Dose Antipsychotic Medication Policy High Dose Antipsychotic Medication Policy Policy Title State previous title where relevant State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For clinical policies

More information

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines

More information

NHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication

NHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS Date 20 th November 2014 Our Ref HDAT_MGPG/Nov14 Enquiries to Caroline Hind Extension 56088 Direct Line 01224 556088 Email caroline.hind2@nhs.net

More information

Document Title Pharmacological Management of Generalised Anxiety Disorder

Document Title Pharmacological Management of Generalised Anxiety Disorder Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)

More information

Prescription of High Dose Antipsychotic Medication

Prescription of High Dose Antipsychotic Medication Subject (M1) Title Medicine Prescription of High Dose Antipsychotic Medication Manual Mental Health Procedure No M1-P-2-MH Department Pharmacy Distribution All Author Rae McKnight Review 4 Reviewer Jonathan

More information

Formulary Item Restrictions and/or Advice Site availability

Formulary Item Restrictions and/or Advice Site availability Formulary Item Restrictions and/or Advice Site availability C&W CNWL Typical Antipsychotic drugs Chlorpromazine 25mg Chlorpromazine 50mg Chlorpromazine 100mg Chlorpromazine 25mg/5ml syrup Chlorpromazine

More information

Antipsychotic Prescribing Audit:

Antipsychotic Prescribing Audit: Antipsychotic Prescribing Audit: Measuring the impact of a prescribing intervention Audit Co-ordinator/ Author of Report: Supervisor: Professor Shôn W Lewis Table of Contents List of Tables... 3 List of

More information

HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT)

HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT) HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT) Document Reference Version Number 2.00 High Dose Antipsychotic Guidelines (HDAT) G376 Author/Lead Job Title Jackie Stark Principal Pharmacist Clinical Services

More information

Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)

Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting

More information

POLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016

POLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016 POLICY DOCUMENT Document Title High dose and combination antipsychotic guidance Reference Number n/a Policy Type Prescribing and Treatment Guideline Electronic File/Location Clinical Resources/Pharmacy/Prescribing

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside

More information

Treatment of Schizophrenia Appendix Three Page 1 of 8

Treatment of Schizophrenia Appendix Three Page 1 of 8 Prescribing Guidelines Treatment of Schizophrenia Scope of this guidance This guidance aims to describe the pharmacological management of schizophrenia at a simple and intermediate level, with a brief

More information

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some

More information

This factsheet covers:

This factsheet covers: Antipsychotics If you experience psychosis as part of your illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar

More information

PORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016

PORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016 Appendix 3. Comparison of recommendations from clinical practice guidelines. Data extracted in relation to key health questions that are relevant to a clinician adopting an algorithmic approach to the

More information

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine

More information

Guidance on the Use of Antipsychotic Long-acting Injections in North of England

Guidance on the Use of Antipsychotic Long-acting Injections in North of England Guidance on the Use of Antipsychotic Long-acting Injections in North of England This guidance aims to inform and support prescribers within the three mental health service providers in the north of England

More information

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction

More information

Antipsychotics. This factsheet covers -

Antipsychotics. This factsheet covers - Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder

More information

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017 Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic

More information

National Clinical Audit of Psychosis (NCAP) Audit of practice form. Notes for completion

National Clinical Audit of Psychosis (NCAP) Audit of practice form. Notes for completion National Clinical Audit of Psychosis (NCAP) Audit of practice form tes for completion Audit forms should be completed by the psychiatrist accountable for the patient's care If delegated, the psychiatrist

More information

Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults

Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice

More information

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Treatment of Schizophrenia

Treatment of Schizophrenia Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,

More information

Guidance on the Use of Antipsychotics

Guidance on the Use of Antipsychotics Guidance on the Use of Antipsychotics Version 3 (October 2015) GUIDELINE NO RATIFYING DRUGS AND THERAPEUTICS GROUP COMMITTEE DATE RATIFIED DATE AVAILABLE ON INTRANET NEXT REVIEW DATE October 2017 ORIGINAL

More information

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated

More information

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

Guidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version)

Guidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version) Guidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version) This guidance aims to inform and support prescribers within the three mental health service providers in the

More information

Birmingham and Solihull Mental Health NHS Foundation Trust. Formulary. March 2013

Birmingham and Solihull Mental Health NHS Foundation Trust. Formulary. March 2013 Birmingham and Solihull Mental Health NHS Foundation Trust Formulary March 2013 1 Table of contents Antipsychotics Introduction p3 1. Antipsychotics available p4 2. Mood stabilisers available p5 3. Prescribing

More information

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) Introduction Aripiprazole long-acting injection (LAI)is licensed for the maintenance treatment of adult patients with schizophrenia

More information

Formulary and Prescribing Guidelines

Formulary and Prescribing Guidelines Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary

More information

Medicines Guideline: High-dose antipsychotic prescribing (MG01)

Medicines Guideline: High-dose antipsychotic prescribing (MG01) Medicines Guideline: High-dose antipsychotic prescribing (MG01) Document author Assured by Review cycle Ben Browning, Locality Lead Pharmacist (Secure Services) MOG sub-group (04.05.16) Review every two

More information

ESSENTIAL SHARED CAR E AGREEMENT FOR

ESSENTIAL SHARED CAR E AGREEMENT FOR E093 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in People with Learning Disability (LD) Referral Criteria In some

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE

AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE Topic AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE Scope 4.3.1 (a) Review question(s)

More information

Prescribing of high-dose and combined antipsychotics for patients on forensic wards.

Prescribing of high-dose and combined antipsychotics for patients on forensic wards. POMH-UK Topic 3 baseline May 2007 Prescribing of high-dose and combined antipsychotics for patients on forensic wards. Prepared by the Prescribing Observatory for Mental Health (POMH-UK) for member Healthcare

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish

More information

New Medicines Committee Briefing November 2011

New Medicines Committee Briefing November 2011 New Medicines Committee Briefing November 2011 Paliperidone long-acting injection (Xeplion ) for schizophrenia Paliperidone palmitate long-acting injection (Xeplion ) is to be reviewed for use within:

More information

Antipsychotic Medication: Monitoring Side Effects

Antipsychotic Medication: Monitoring Side Effects Antipsychotic Medication: Monitoring Side Effects Aims Review national practice guidelines and evidence regarding current standards of care. Discuss clinical implications of AP side effects. Reflect on

More information

Antipsychotics. BMF 84 - Antipsychotics

Antipsychotics. BMF 84 - Antipsychotics Antipsychotics BMF 84 - Antipsychotics Antipsychotic medications (neuroleptics) are used for the treatment of psychosis, mainly schizophrenia and manic depression (bipolar disorder). They reduce symptoms

More information

Safe transfer of prescribing guidance

Safe transfer of prescribing guidance Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy

More information

PRESCRIBING GUIDELINES

PRESCRIBING GUIDELINES The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors

More information

Choosing and delivering ering interventions entions for

Choosing and delivering ering interventions entions for Choosing and delivering ering interventions entions for psychosis and schizophrenia in adults bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Schizophrenia in Greater Manchester: Audit

Schizophrenia in Greater Manchester: Audit S i G M A Schizophrenia in Greater Manchester: Audit SiGMA Schizophrenia in Greater Manchester: Audit Report 2011-2012 Audit Co-ordinator/ Author of Report: Project Lead Applicants: Darragh Downey, Karen

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file

More information

Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services

Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services NHS GGC Mental Health Service Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services Important Note: The Intranet version of this document

More information

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer

More information

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service

More information

PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE. Chief Pharmacist. Chief Pharmacist

PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE. Chief Pharmacist. Chief Pharmacist REFERENCE NUMBER: PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE AREA: NAME OF RESPONSIBLE COMMITTEE / INDIVIDUAL NAME OF ORIGINATOR / AUTHOR Trust-wide Chief Pharmacist Chief Pharmacist DATE

More information

Proposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

Proposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) Proposed Changes to Existing Measure for HEDIS 1 2020: Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) NCQA seeks comments on proposed modifications to the HEDIS Health

More information

LAI Antipsychotics Frequently Asked Questions

LAI Antipsychotics Frequently Asked Questions LAI Antipsychotics Frequently Asked Questions Click each question to see the answer. Click the link to return to this list. Who should receive LAIs (long acting injectable antipsychotics)? Which antipsychotics

More information

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Ref No: E050 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Please complete the following details: Patient s name,

More information

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second

More information

The licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia.

The licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia. 1. Introduction Future Directions CIC will support the use of the antipsychotic Clozapine in all appropriate cases. The purpose of this procedure is to set out the standards for Clinicians, Pharmacists,

More information

Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults

Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Shared Care Guideline for the treatment of Tourette s Syndrome and other tic disorders in children and adolescents. Scope: Version: Pennine Care NHS Foundation Trust NHS Bury NHS

More information

paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd

paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd Re-Submission paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd 07 October 2011 The Scottish Medicines Consortium

More information

Prescribing of high-dose and combination antipsychotics on adult acute and intensive care wards: Clinical introduction, methodology and glossary.

Prescribing of high-dose and combination antipsychotics on adult acute and intensive care wards: Clinical introduction, methodology and glossary. POMH-UK Topic 1 report 1b Prescribing of high-dose and combination antipsychotics on adult : Clinical introduction, methodology and glossary. March 2007 Prepared by the Prescribing Observatory for Mental

More information

Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly

Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly Overall Comprehensive Research Plan: Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly October 9, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca

More information

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements Schizophrenia Bulletin vol. 36 no. 1 pp. 71 93, 2010 doi:10.1093/schbul/sbp116 Advance Access publication on December 2, 2009 The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: Ongoing care for adults with psychosis or schizophrenia bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop

More information

Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act

Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act This guidance is intended for Coventry and Warwickshire Partnership Trust staff to use when

More information

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:

More information

ANTIPSYCHOTIC GUIDELINES

ANTIPSYCHOTIC GUIDELINES ANTIPSYCHOTIC GUIDELINES TREATMENT OF SCHIZOPHRENIA AND PSYCHOSIS Page 1 of 44 Authors: Ms Diane Booth, Chief Pharmacist,. Mrs Kiran Hewitt, Lead Clinical Pharmacist, Berkshire Healthcare NHS Foundation

More information

University of Groningen. Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia

University of Groningen. Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia University of Groningen Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

High Dose Antipsychotic Treatment (HDAT) Guideline In-patient and Community Patient

High Dose Antipsychotic Treatment (HDAT) Guideline In-patient and Community Patient High Dose Antipsychotic Treatment (HDAT) Guideline In-patient and Community Patient Lead Author: Endorsing Body: Governance or Assurance Committee Lesley Dewar Implementation Date: April 2018 Version Number:

More information

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08. Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important

More information

Joint Formulary for Psychotropic Medication.

Joint Formulary for Psychotropic Medication. Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories

More information

This document has been produced in collaboration with the Lancashire Commissioning Support Unit

This document has been produced in collaboration with the Lancashire Commissioning Support Unit Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Date: December 2014. Reviewed August 2016. Next review Date April 2019

More information

Initiation of Clozapine Treatment Community Patients

Initiation of Clozapine Treatment Community Patients Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A Initiation of Clozapine Treatment for Patients in the

More information

Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155

Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155 Psychosis and schizophrenia in children and young people: recognition and management Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155 NICE 2017. All rights reserved. Subject to

More information

Optima Health. Schizophrenia. Next Review Date 9/19

Optima Health. Schizophrenia. Next Review Date 9/19 Optima Health Schizophrenia Guideline History Original Approve Date 04/01 Review/Revise 3/05, 12/06, 09/08, 11/08, Dates 11/10, 7/11, 7/13, 7/15, 9/17 Next Review Date 9/19 These Guidelines are promulgated

More information

This shared care protocol covers when atypical antipsychotics are prescribed for the treatment of

This shared care protocol covers when atypical antipsychotics are prescribed for the treatment of SHARED CARE PROTOCOL for ATYPICAL ANTIPSYCHOTICS SCOPE Greater Manchester West Mental health NHS Foundation Trust Bolton Primary Care Trust Salford Primary Care Trust Trafford Primary Care Trusts Issue

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES?

CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES? CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES? C.A.W. Rijcken 1, T.B.M. Monster 1, J.R.B.J. Brouwers 1, L.T.W. de Jong van den Berg 1 1 Department of Social

More information

DEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING

DEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING DEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING DECEMBER 2016 This policy supersedes all previous policies Policy title Depot Antipsychotic Medication: Guidelines for Prescribing

More information

PALIPERIDONE (Trevicta ) 3 MONTHLY Long acting injection (LAI) Guidance for Prescribing and Administration

PALIPERIDONE (Trevicta ) 3 MONTHLY Long acting injection (LAI) Guidance for Prescribing and Administration PALIPERIDONE (Trevicta ) 3 MONTHLY Long acting injection (LAI) Guidance for Prescribing and Administration Paliperidone 1 monthly long acting injection (Xeplion ) This is included in the Trust medicines

More information

Antipsychotic Medications Age and Step Therapy

Antipsychotic Medications Age and Step Therapy Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana

More information

S H A R E D P R E S C R I B I N G G U I D E L I N E

S H A R E D P R E S C R I B I N G G U I D E L I N E S H A R E D P R E S C R I B I N G G U I D E L I N E Introduction This shared prescribing guideline for the second generation antipsychotic medications listed above has been developed with due consideration

More information

Datix Ref:

Datix Ref: Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log

More information